Liu Baolin, Hao Jianqiang, Pan Yisheng, Luo Bin, Westgard Britt, Heremans Yves, Sutherland David E R, Hering Bernhard J, Guo Zhiguang
Department of Surgery, Diabetes Institute for Immunology and Transplantation, University of Minnesota, Minneapolis, MN, USA, and Department of Surgery, Second Affiliated Hospital, China Medical University, China.
Am J Transplant. 2006 May;6(5 Pt 1):933-46. doi: 10.1111/j.1600-6143.2006.01283.x.
Inducing donor chimerism is the most consistently successful approach to achieve transplant tolerance. We found that a low level of donor chimerism, which was induced by a relatively non-toxic approach, induced donor-specific tolerance to islet allografts in chemically induced diabetic mice. However, a similar level of donor chimerism could not protect donor islet allografts in non-obese diabetic (NOD) mice that spontaneously developed autoimmune diabetes. Rejection of donor islet allografts in diabetic NOD mice with a low level of donor chimerism was mediated by recurrent autoimmunity. We used post-transplant donor lymphocyte infusion (DLI) to increase donor chimerism and to induce tolerance to islet allografts. DLI significantly increased donor chimerism and promoted donor-specific tolerance to islet allografts in diabetic NOD mice. Self-tolerance to islet autoantigens was restored and restoring self-tolerance is mediated by immunoregulation. Thus, our data showed that adoptive immunotherapy with post-transplant DLI after establishing a low level of donor chimerism as a platform enhances donor chimerism, induces donor-specific tolerance to islet allografts and restores self-tolerance in the setting of autoimmune diabetes. Our data also showed that central tolerance is not sufficient to induce tolerance and peripheral tolerance through immunoregulation for restoring self-tolerance is required in the setting of autoimmune diabetes.
诱导供体嵌合体是实现移植耐受最持续成功的方法。我们发现,通过相对无毒的方法诱导产生的低水平供体嵌合体,能使化学诱导糖尿病小鼠对胰岛同种异体移植产生供体特异性耐受。然而,类似水平的供体嵌合体并不能保护非肥胖糖尿病(NOD)小鼠(其自发发展为自身免疫性糖尿病)的供体胰岛同种异体移植。糖尿病NOD小鼠中低水平供体嵌合体情况下供体胰岛同种异体移植的排斥是由复发性自身免疫介导的。我们采用移植后供体淋巴细胞输注(DLI)来增加供体嵌合体并诱导对胰岛同种异体移植的耐受。DLI显著增加了糖尿病NOD小鼠的供体嵌合体,并促进了对胰岛同种异体移植的供体特异性耐受。对胰岛自身抗原的自身耐受得以恢复,且自身耐受的恢复是由免疫调节介导的。因此,我们的数据表明,在建立低水平供体嵌合体作为平台后,通过移植后DLI进行过继性免疫治疗可增强供体嵌合体,诱导对胰岛同种异体移植的供体特异性耐受,并在自身免疫性糖尿病背景下恢复自身耐受。我们的数据还表明,中枢耐受不足以诱导耐受,在自身免疫性糖尿病背景下需要通过免疫调节的外周耐受来恢复自身耐受。